Lenvatinib, a molecular‐targeted agent that inhibits key receptors involved in tumor angiogenesis—including the vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors—has proven to be an effective treatment for such patients [10]. Here, VEGFA is linked to neoplasm.